Abbvie receives $ 2.1bn Capstan by adding a new addition to the pipeline Vivo car-t

Abbvie, Vivo Car-T, Vivo car-t candidate Vivo car-T candidate “high-risk, high-winning, high-winning” clinical stage agreed to acquire therapeutics.

Capstan is a type of type of new car-type, which eliminates restrictions with current options. Currently, this method has financial and dimensional obstacles in this method, along with the requirement of the patient’s ability to combat cancer cells, but in this method, in addition to lenphodepleter chemistry.

Capstan’s lead asset, CPTX2309, a Vivo targeted Lipid Nanoparticle (LNP) that can solve these problems is Anti-CD19 car therapy. Abbvie, of course, is the promise to pay $ 2.1 billion in $ 2.1 billion, along with RNA loading technology, which is used to create other prinical programs and RNA.

CPTX2309 is evaluated at a stage of developed, healthy volunteers (NCT06917742), developed for the treatment of autoimme diseases with B-cell mediation. The initial review of the information from Capstan reveals strong B-cell depletion – the purpose of treatment is to achieve ‘immune reset’ by repeating healthy B cells.

Investors shared a positive mood, the Shares shared by the list listed in NYSE, June 30.62 about 185.62, the day of the day. Big Pharma’s market cap has $ 327.9 billion.

In January 2024, Umoja collaborated with Biopharma, Abbvie’s Vivo Car-T in his relations with Umoja Biopharma. This partnership allows Abbvie to develop cy celikatical candidates in oncology using Umoja’s vivovecplatform.

William Blair Analyst Matt Phipps, “Even if the CPTX2309 is still in the early clinical development, it is a strategic effort by Abbvie to further strengthen Abbvie’s immunological franchison through novel, disease-changing mechanisms.

“Taking into account the developmental phase, this asset is clearly incoming in Clinical Risk, but considered the potential for the potential for the potential for production intensity, which does not require a lenfodeplet.

Phipps, characterizing the new asset of Abbvie’s new asset as “high-risk, high-winning”, said that Abbvie has combined the purchase of strong trade. Big Pharma has already She has squeezed Skyrizi (Risankizumab) and the loss of market exclusivity for Blockbuster Humira (Adalimumaab) spreading by spreading Rinvio (Upadacitinib).